Drugs / Interferon gamma human recombinant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05156541 | May 2009 → Jun 2010 | anogenital human papillomavirus infection | SPP Pharmaclon Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05378646 | Jan → Dec 2009 | chronic prostatitis | SPP Pharmaclon Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05054114 | Dec 2020 → May 2021 | COVID-19, lung disorder | SPP Pharmaclon Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon gamma human recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054114 ↗ |
| Known as | IFN-G | “Interferon gamma human recombinant (IFN-G)” NCT05378646 ↗2“Interferon gamma human recombinant (IFN-G)” NCT05054114 ↗ “Interferon gamma human recombinant (IFN-G)” NCT05156541 ↗ |
| Modality | Protein / enzyme biologic | “specific antiviral activity on cells is 2x10\*7 Units per mg of protein” NCT05378646 ↗ |
| Route | Intranasal | “nasal form” NCT05054114 ↗ |